Lucas E. Wong
Expertise in
20
conditions

Dr. Lucas E. Wong

Oncology
2401 S 31st St, 
Temple, TX 
Accepting New Patients
Offers Telehealth
Expertise in
20
conditions
2401 S 31st St, 
Temple, TX 

Overview

Dr. Wong's focus has been on gastrointestinal cancer patients and clinical research in the area of GI cancers. He provides education in this same area for the Baylor College of Medicine Medical School, Baylor Scott & White internal medicine residency, and Baylor Scott & White hematology/oncology fellowship program. He is currently a Clinical Professor of Medicine at the BCM Medical School. Outside of Baylor Scott & White, he is a board member of the Texas Society of Clinical Oncology, Texas Medical Association Cancer Committee member, and SWOG GI committee member. Dr. Wong's area of clinical care and research is gastrointestinal malignancies such as colon, pancreatic, esophageal, stomach, liver, bile duct, rectal, anal, and small bowel. Connect with Dr. Wong: Baylor College of Medicine.

Dr. Wong is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Pancreatic Cancer, Familial Pancreatic Cancer, Bone Marrow Aspiration, and Endoscopy.

Dr. Wong is board certified in Internal Medicine- American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 26 peer reviewed articles and participating in 25 clinical trials. Dr. Wong is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in TX

Board Certifications

Internal Medicine- American Board Of Internal Medicine

Fellowships

Hematology/Oncology, University of Arizona/Arizona Cancer Center - 1994

Hospital Affiliations

Baylor Scott & White Medical Center - Marble Falls
Baylor Scott & White Medical Center -Taylor
Baylor Scott & White Medical Center Hillcrest
Baylor Scott & White Medical Center - Temple
Baylor Scott & White Continuing Care Hospital - Temple
Baylor Scott & White Medical Center - Temple

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
FirstCare
  • HMO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Scott and White Health
  • HMO
  • POS
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Baylor Scott & White Vasicek Cancer Treatment Center - Temple
2401 S 31st St, Temple, TX 76508

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

25 Clinical Trials

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
Phase II, Open-label, Single Arm, Multicenter Study of Encorafenib, Binimetinib Plus Cetuximab in Subjects With Previously Untreated BRAF V600E -Mutant Metastatic Colorectal Cancer
Phase II, Open-label, Single Arm, Multicenter Study of Encorafenib, Binimetinib Plus Cetuximab in Subjects With Previously Untreated BRAF V600E -Mutant Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: July 16, 2026
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
Study Phase: Phase 3
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
Enrollment Status: Completed
Publish Date: February 10, 2026
Intervention Type: Device, Biological, Other, Drug
Study Drugs: Cetuximab, Irinotecan, Pertuzumab, Trastuzumab
Study Phase: Phase 2
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: January 21, 2026
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
View 9 Less Clinical Trials

26 Total Publications

Increasing incidence of hepatobiliary cancer in adolescents and young adult females: a Surveillance, Epidemiology, and End Results database study.
Increasing incidence of hepatobiliary cancer in adolescents and young adult females: a Surveillance, Epidemiology, and End Results database study.
Journal: Proceedings (Baylor University. Medical Center)
Published: August 07, 2026
Similar Doctors
Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

Baylor Scott & White Vasicek Cancer Treatment Center - Temple

2401 S 31st St, 
Temple, TX 
 (0.1 miles away)
254-724-5918
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

After completing his residency and fellowship at Scott & White, Dr. Gowan has spent his entire 20-year professional career in Temple, TX. Initially, he was at Scott & White Memorial which became Baylor Scott & White Health. His primary focus is on thoracic cancers and malignancies of the head and neck. Dr. Gowan's areas of expertise include lung cancer and head and neck cancer. Dr. Gowan is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), Bone Marrow Aspiration, and Endoscopy. Dr. Gowan is board certified in Medical Oncology- American Board Of Internal Medicine. Dr. Gowan is currently accepting new patients.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Baylor Scott & White Vasicek Cancer Treatment Center - Temple

2401 S 31st St, 
Temple, TX 
 (0.1 miles away)
254-724-5918
Languages Spoken:
English, Hindi, Kannada
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Bhat is a board-certified hematologist/ medical oncologist who has formed a niche in breast oncology. She joined BSW at Temple's main campus in 2011 soon after completing her fellowship, and her medical practice mostly consists of breast cancer patients. She also supervises the trainee fellows in their continuity clinic and is one of the core faculty in Baylor Scott & White's 3-year hem-oncology fellowship program. Dr. Bhat has been the site director of NSABP and is currently the chair of the breast tumor board, a weekly interdisciplinary case discussion conference, where NCCN guidelines and optimal treatment options for all their breast cancer patients are discussed. She is passionate about taking care of breast cancer patients and believes in providing them with a comprehensive, yet personalized care plan when it comes to their cancer. Their clinic offers several state-of-the-art treatments like novel chemotherapies, biotherapies, targeted therapies, and immunotherapies. In addition to these standard treatments, she strives to bring on relevant and pertinent clinical trials that would benefit our breast cancer patients. She frequently offers second and third-opinion consults on complicated cases that are referred from our peripheral clinics. Dr. Bhat is highly rated in 23 conditions, according to our data. Her clinical expertise encompasses Angiosarcoma, Inflammatory Breast Cancer, Breast Cancer, Bone Marrow Aspiration, and Endoscopy. Dr. Bhat is board certified in Medical Oncology- American Board Of Internal Medicine and Hematology- American Board Of Internal Medicine. Dr. Bhat is currently accepting new patients.

Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required

Scott & White Memorial Hospital

2401 S 31st St, 
Temple, TX 
 (0.1 miles away)
254-724-2111
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Charles Capen is an Oncologist practicing medicine in Temple, Texas. Dr. Capen is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Vulvar Cancer, Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, and Ovarian Cancer. Dr. Capen is currently accepting new patients.

Frequently Asked Questions about Dr. Lucas E. Wong

How do I make an appointment with Dr. Lucas E. Wong?

You can book an appointment with Dr. Lucas E. Wong by calling their office at 254-724-5918. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Lucas E. Wong a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Lucas E. Wong is classified as an Distinguished expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Lucas E. Wong specialize in?

While Dr. Lucas E. Wong is a Oncology, they have specific expertise in Colorectal Cancer, Pancreatic Cancer, and Familial Pancreatic Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Lucas E. Wong participate in research or clinical trials?

Yes. Dr. Lucas E. Wong has published 26 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Lucas E. Wong's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Lucas E. Wong accept my insurance?

Dr. Lucas E. Wong accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 254-724-5918 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wong's expertise for a condition
ConditionClose
    View All 15 Advanced Conditions
    View All 65 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile